EDDING GENOR GROUP(06998.HK): IND Approval Granted by NMPA for Phase Ib/II Clinical Trial of GB268

NewTimeSpace · 2026/07/03 08:05 · By Xuran Lin

NewTimeSpace News: EDDING GENOR GROUPannounced in a July 2 announcement that the Investigational New Drug (IND) application for GB268, its highly differentiated innovative PD-1/CTLA-4/VEGF trispecific antibody, has been approved by the National Medical Products Administration (NMPA) for a Phase Ib/II clinical trial treating locally advanced unresectable or metastatic breast cancer.

NewTimeSpace News: On July 2, 2026, EDDING GENOR GROUP(06998.HK) announced that the NMPA has approved the Phase Ib/II IND application for GB268 indicated for locally advanced unresectable or metastatic breast cancer. The trial will evaluate monotherapy regimens, immunotherapy combined with chemotherapy, and immunotherapy combined with ADC drugs across first-line and later-line treatment settings.

According to the announcement, the IND approval is supported by robust monotherapy clinical data and a rational combination therapeutic mechanism of GB268. The dose-escalation study of GB268 has advanced to 30 mg/kg with no dose-limiting toxicity (DLT) observed. Phase I monotherapy clinical data is scheduled to be presented at ESMO in the fourth quarter of 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

EDDING GENOR GROUP 06998.HK